Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 310-318

  Hochman, Jerome H ^a   Chiba, Masato ^a   Nishime, Joy ^a   Yamazaki, Masayo ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; DRUG METABOLITE; GLYCOPROTEIN P; INDINAVIR;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CHOLECALCIFEROL; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INTESTINAL ABSORPTION; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033957756     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Artursson P, Palm K and Luthman K (1996) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22:67-84.
2. Bailey CA, Bryla P and Malick AW (1996) The use of intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv Drug Deliv Rev 22:85-104.
3. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Duetsch PJ, Yeh KC and Lin JH (1996) Disposition of indinavir, a potent HIV-1 protease inhibitor, after oral dose in humans. Drug Metab Dispos 24:1389-1394.
4. Chiba M, Hensleigh M and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 53:1187-1195.
5. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:307-313.
6. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed, MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
7. Floren LC, Berkersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Hebert MF (1997) Tacrolimus oral unavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
8. Fricker G, Drewe J, Huwyler J, Gutmann H and Beglinger, C (1996) Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118: 1841-1847.
9. Gan L-S L, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW and Thakker DR (1996) CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: Interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 24:344-349.
10. Gatmaitan Z and Arias I (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Acta Pharmacol 24:77-97.
11. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
12. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
13. Hidalgo IJ and Li J (1996) Carrier-mediated transport and efflux mechanisms in Caco-2 cells. Adv Drug Deliv Rev 22:53-66.
14. Ito K, Kusuhara H and Sugiyama Y (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption: Theoretical approach. Pharm Res 16:225-231.
15. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
16. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
17. Leu B-L and Huang J-D (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432-436.
18. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY-S, Vastag KJ and Nishime JA (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
19. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Gou WS and Watkins PB (1997b) Grapefruit juice increases felodipine oral availability in human by decreasing intestinal CYP 3A protein expression. J Clin Invest 99:2545-2553.
20. Lown KS, Mayo RR, Leichtman AB, Hsiao H-L, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins PB (1997) Role of intestinal P-glycoprotein (mdr-1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
21. Paine MF, Khalighi M, Fisher JM, Shen DD, Kuntze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human Cyp3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
22. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
23. Pinto M, Rubine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, LaCroix B, Simon-Assman P, Haffen K, Fogh J and Zweibaum A (1983) Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330.
24. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO and Vyas KP (1996) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634-642.
25. Salphati L and Benet LZ (1998a) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
26. Salphati L and Benet LZ (1998b) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rats. Biochem Pharmacol 55:387-395.
27. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170.
28. 3. J Pharmacol Exp Ther 51:741-754.
29. Schuetz EG, Beck WT and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
30. Wacher VJ, Silverman JA, Zhang Y and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
31. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
32. Washington CB, Duran GE, Man MC, Sikic BI and Blaschke T (1998) Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syn Hum Retroviruses 19:203-209.
33. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
34. Watkins PB, Wrighton SA, Scheutz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
35. Zhang Y, Hsieh Y, Izumi T, Lin ET and Benet LZ (1998) Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of KO2, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246-252.